| Autor: |
Fassbender, W. J., Gödde, M., Brandenburg, V. M., Usadel, K. H., Stumpf, U. C. |
| Předmět: |
|
| Zdroj: |
Advances in Medical Sciences (De Gruyter Open); 2009, Vol. 54 Issue 1, p1-6, 6p, 2 Charts, 6 Graphs |
| Abstrakt: |
Purpose: Deoxypyfidinoline (DPD) is a derivative of hydroxypyridinium, which is released during bone resorption into the blood stream and is eliminated unmodified with urine. A further collagen-derived marker of bone resorption is the C-terminal telopeptide of type I collagen (β-CTX-L here abbreviated as CTX), which is released in bone resorption and almost entirely excreted by the kidneys. The aim of our study was to investigate different well-described patient groups as well as normal probands in view of differences and expected correlations of these two parameters: patients with insulin-dependent diabetes mellitus, postmenopausal women with osteoporosis and healthy control persons. Materials and Methods: We used a solid-phase chemiluminescence enzyme immunoassay (Pyrilinks D-IMMULITE) for urinary DPD measurement and for the assessment of urinary CTX we used a quantitative ELISA (Osteometer Biotec A-S, CrossLaps®ELISA). Results:We found a highly significant correlation between both parameters in the group of healthy persons (r = 0 75;,p < 0 05, n = 28) as well as in the group of patients with diabetes mellitus type I (r = 0 79; p <0 05; n = 65). Also, a significant correlation was observed between DPD and CTX(r = 0.583, p < 0.05, n = 88) in the group of female, osteoporofic patients. Conclusions: Despite good correlations between DPD and CTX in all of the investigated groups, these urinary markers were of limited diagnostic significance in the group of postmenopausal osteoporosis due to a wide spread (few patients showed concentrations above the range of healthy persons) in this newly diagnosed drug-naïve patient collective. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
